Research,
Genetics,
Health Technology,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Patient,
Nanobiotechnology,
Messenger,
Therapy,
School,
RNA Biology,
RNA,
Bloomberg,
Johns Hopkins University,
Johns Hopkins,
Pharmaceutical industry TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.
Key Points:
- TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.
- A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.
- TriLink’s investment includes direct funding for the center and access to TriLink’s proprietary in vitro transcription technology, CleanScript™, which will enable Hopkins researchers to advance mRNA development.
- Schlesinger adds that the availability of cutting-edge discovery tools will enable Johns Hopkins to grow its RNA research community and increase the cycle of innovation on campus.
Research,
General Health,
Pharmaceutical,
Oncology,
Infectious Diseases,
Clinical Trials,
Science,
Cardiology,
Biotechnology,
Neurology,
Other Science,
Health,
AG,
Vaccine,
SaRNA,
Messenger This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
Key Points:
- This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
- CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
- “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines.
- In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6 , with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
Other Health,
Research,
General Health,
Pharmaceutical,
Oncology,
Infectious Diseases,
Clinical Trials,
Science,
Medical Supplies,
FDA,
Other Science,
Health,
Safety,
Cancer,
Gene editing,
NTP,
Vaccine,
CDMO,
Melamaravakkadu,
SaRNA,
Biotechnology,
Infection,
Multimedia,
Messenger,
GMP,
COVID-19,
CGMP TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility .
Key Points:
- TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility .
- The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities .
- View the full release here: https://www.businesswire.com/news/home/20240418722567/en/
TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)
Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, increased mRNA capacity (1g to >100g per batch), comprehensive in-house analytical services, and laboratory space for on-site quality control testing.
- TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015.
Retrieved on:
Wednesday, February 21, 2024
Research,
Infectious Diseases,
FDA,
Genetics,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Other Science,
Maker,
Therapy,
Messenger,
CIPO,
Vaccine,
General counsel,
ARCA,
COVID-19,
SaRNA,
CNIPA,
Intellectual property,
Melamaravakkadu,
Human “mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.
Key Points:
- “mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.
- CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines.
- “TriLink’s CleanCap technology is helping to bring life-saving therapeutics and vaccines to market faster,” added Kurt Oreshack, Executive Vice President & General Counsel, Maravai LifeSciences.
- “These additional jurisdictions fortify the validity and strength of our global intellectual property.”
Last May, TriLink launched its most robust analog to date: CleanCap® M6 .
Retrieved on:
Thursday, November 2, 2023
FDA,
Health,
Infectious Diseases,
Research,
Science,
Biotechnology,
Laboratory,
Dicarboxylic acid,
NMR,
Therapy,
Vaccine,
CDMO,
ASCE,
DNA,
Growth,
NGS,
Melamaravakkadu,
Messenger,
LNP,
Education, Communities and Justice Directorates,
GM,
Quality control,
Fine chemical TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub.
Key Points:
- TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub.
- Expanding its comprehensive suite of analytical testing capabilities, this new center of excellence will minimize the delays and unexpected costs typically associated with outsourced testing to multiple laboratories.
- This new center of excellence will serve as the hub for all analytical innovation and the Quality Control laboratories across the organization’s manufacturing network.
- “TriLink's new Analytical Sciences Center of Excellence will be a transformative force in the development of nucleic acid therapies,” shared Khaled Yamout, Senior Director of Analytical Services at TriLink.
Technology,
Biotechnology,
Nanotechnology,
Health,
Other Health,
Other Construction & Property,
Commercial Building & Real Estate,
Pharmaceutical,
Construction & Property,
Oncology,
Building Systems,
Genetics,
Health Technology,
Cardiology,
Vaccine,
GMP,
DNA,
Melamaravakkadu,
Therapy,
Engineering,
ISO,
Gene editing,
Cancer,
Messenger,
CGMP,
Love,
ISO 7 TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers.
Key Points:
- TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers.
- TriLink has reliably delivered GMP services to its customers since the debut of its first cGMP manufacturing facility in 2015.
- Built to meet the need of a rapidly growing market, the new cGMP facility is expected to contribute to the development of vital mRNA therapeutics.
- “The expansion of our cGMP mRNA manufacturing capabilities marks a major milestone for TriLink and our partners,” said Becky Buzzeo, Chief Commercial Officer at Maravai LifeSciences.
Vaccine,
Melamaravakkadu,
ARCA,
Therapy,
EVP,
COVID-19,
Test pilot,
Messenger,
CDMO,
Adenosine,
SAN,
Biotechnology SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 .
Key Points:
- SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 .
- The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster.
- With the introduction of the CleanCap M6 technology, legacy capping methods like enzymatic and ARCA may be a thing of the past.
- With the introduction of CleanCap M6, TriLink has developed its most robust analog to date.
CleanCap is a co-transcriptional 5' capping technology that generates a natural Cap 1 structure with higher mRNA capping efficiencies.
Key Points:
- CleanCap is a co-transcriptional 5' capping technology that generates a natural Cap 1 structure with higher mRNA capping efficiencies.
- CleanCap increases mRNA yields during transcription, simplifies and shortens the mRNA manufacturing process and results in higher levels of protein production.
- TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap mRNA capping technology.
- TriLink continues to expand its cGMP and general manufacturing capacity at its new global headquarters to support mRNA, oligonucleotide & plasmid therapeutic, vaccine and diagnostic customers.
Retrieved on:
Wednesday, November 20, 2019
SAN DIEGO, Nov. 20,2019 /PRNewswire/ --mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City.
Key Points:
- SAN DIEGO, Nov. 20,2019 /PRNewswire/ --mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City.
- "San Diego has the perfect biotech and life science ecosystem for both Maravai LifeSciences and TriLinkBioTechnologies to continue innovating, and we are laser focused on the next chapter in our growth.
- "Maravai LifeSciences' investment in a San Diego headquarters is testament to the impact of our regional biotech cluster.
- Maravai LifeSciences provides reagents and services to life science researchers and commercial partners to enable breakthrough discoveries and improvements in human health.
